Fallopian Tube High-grade Serous Carcinoma With Intramucosal Spread and Presenting as a Malignancy on Pap Smear

2014 ◽  
Vol 33 (4) ◽  
pp. 443-448 ◽  
Author(s):  
Zuzana Kos ◽  
Russell R. Broaddus ◽  
Bojana Djordjevic
2016 ◽  
Vol 6 (12) ◽  
pp. 1309-1311 ◽  
Author(s):  
Elizabeth M. Swisher ◽  
Rochelle L. Garcia ◽  
Mark R. Kilgore ◽  
Barbara M. Norquist

The Breast ◽  
2019 ◽  
Vol 44 ◽  
pp. S65
Author(s):  
T. Kulkovská ◽  
D. Vlčáková ◽  
P. Slávik ◽  
Z. Laučeková ◽  
T. Bielik ◽  
...  

2018 ◽  
Vol 2018 ◽  
pp. 1-4 ◽  
Author(s):  
Felicity Harl ◽  
Cassandra Niemi ◽  
Lori Mankowski Gettle ◽  
Paul Weisman ◽  
Stephen Rose

A 68-year-old woman presented with a three-week history of confusion and anomic aphasia. Imaging of her head demonstrated a single large left frontal mass. Pathology revealed metastatic adenocarcinoma of Müllerian origin. Subsequent surgery revealed a small primary site in a fallopian tube, high left para-aortic lymphadenopathy, and no disseminated intraperitoneal disease. This case was remarkable in that CNS metastasis was her presenting symptom and was restricted to a solitary brain lesion, and other disease sites were limited to retroperitoneal lymphadenopathy and a small fallopian tube primary.


2016 ◽  
Vol 26 (6) ◽  
pp. 1012-1019 ◽  
Author(s):  
Tayfun Toptas ◽  
Elif Pestereli ◽  
Onur Erol ◽  
Selen Bozkurt ◽  
Gulgun Erdogan ◽  
...  

ObjectiveThis study aimed to evaluate the prognostic significance of revised International Federation of Gynecology and Obstetrics (FIGO2013) staging classification for cancer of the ovary, fallopian tube, and peritoneum in patients exhibiting high-grade serous histology.MethodsClinical records of patients with high-grade serous carcinoma who underwent primary surgery between 2007 and 2012 were reviewed retrospectively. Patients were reclassified according to the FIGO2013 criteria. Progression-free survival (PFS) and overall survival (OS) were calculated for each stage using Kaplan-Meier estimates and compared with the log-rank test.ResultsIn total, 125 patients were included in the analysis. The distribution of the study cohort according to the revised classification was as follows; stage I, 6 patients; stage II, 9 patients; stage III, 85 patients; and stage IV, 25 patients. Median follow-up time was 36 months (95% confidence interval [CI], 3–110). The median PFS and OS were 14 months (95% CI, 12.4–15.6) and 60 months (95% CI, 47.0–72.9), respectively. Both PFS and OS were significantly different among stages I, II, III, and IV (P < 0.01). Subgroup analyses for stage III disease also revealed significant differences in survival. The median PFS for stages IIIA1, IIIB, and IIIC was 56, 46, and 16 months, respectively (P < 0.01), and the median OS was 104, 95, and 60 months, respectively (P = 0.03). The outcomes of patients with stage IV disease differed slightly but nonsignificantly according to new substages. The median PFS for stages IVA and IVB was 12 and 6 months, respectively (hazard ratio, 1.16; 95% CI, 0.48–2.79; P = 0.72), and the median OS was 41 and 24 months, respectively (hazard ratio, 1.62; 95% CI, 0.58–4.55; P = 0.35). The study sample was insufficient in size for subgroup analyses in stages I and II.ConclusionsThe revised FIGO2013 staging system is highly prognostic for discriminating outcomes of patients with high-grade serous carcinoma across stages I to IV, in subgroups of stage III, but not in subgroups of stage IV.


Diagnostics ◽  
2020 ◽  
Vol 10 (2) ◽  
pp. 120 ◽  
Author(s):  
Isao Otsuka ◽  
Takuto Matsuura

High-grade serous carcinoma (HGSC) is the most common and lethal subtype of ovarian carcinoma. Many HGSCs are now believed to originate in the fallopian tube epithelium; ovarian surface epithelium is another possible origin. Thus, current screening methods, i.e., ultrasonography and serum CA-125 measurements, have a limitation in their early detection. Recently, circulating biomarkers, such as tumor DNA, autoantibody, and microRNA, have been investigated to detect HGSCs. As cancer cells in the fallopian tube flow into the endometrial cavity, the detection of exfoliated cells, tumor DNA, and proteome from samples obtained from the endometrial cavity or the cervix may be useful. The risk of ovarian serous carcinoma is affected by the use of oral contraceptive and menopausal hormone therapy (MHT). MHT regimens causing endometrial bleeding increase serous carcinoma risk, hence, incessant retrograde bleeding from the endometrial cavity into the Douglas pouch appears to play an important role in high-grade serous carcinogenesis. In this review, we provide an overview of current and novel screening methods and prevention approaches for ovarian and fallopian tube HGSC.


2020 ◽  
Vol 95 (10) ◽  
pp. 2300-2301
Author(s):  
J. Kenneth Schoolmeester ◽  
Lori A. Erickson

Sign in / Sign up

Export Citation Format

Share Document